• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

cold agglutinin disease (CAD)

Enjaymo: First Drug to Treat Cold Agglutinin Disease
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Enjaymo: First Drug to Treat Cold Agglutinin Disease

February 9, 2022September 8, 2022

Sutimlimab will reduce the need for red blood cell transfusion due to hemolysis.

blood
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria

May 20, 2021September 8, 2022

Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News